Literature DB >> 3285216

Thrombolytic therapy: current status (1).

V J Marder1, S Sherry.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 3285216     DOI： 10.1056/NEJM198806093182306

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  58 in total

1.  A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator.

Authors:  G L Reed; A K Houng; L Liu; B Parhami-Seren; L H Matsueda; S Wang; L Hedstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 2.  New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.

Authors:  A V Maksimenko; E G Tischenko
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 3.  Thrombolytic therapy in acute myocardial infarction.

Authors:  U Priglinger; K Huber
Journal:  Drugs Aging       Date:  2000-04       Impact factor: 3.923

4.  Enhancement of fibrinolysis in vitro by ultrasound.

Authors:  C W Francis; P T Onundarson; E L Carstensen; A Blinc; R S Meltzer; K Schwarz; V J Marder
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

5.  Thrombolytic therapy for acute myocardial infarction. Lessons to be learned.

Authors:  S Sherry
Journal:  Tex Heart Inst J       Date:  1991

6.  French multicenter trial of anistreplase versus heparin in acute myocardial infarction.

Authors:  H Lardoux; Y Louvard; D de Vernejoul; C Picot; M Baudet; M Hiltgen; M Houplon; J Ponsonnaille; M Richard; R Luccioni
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

7.  Ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro porcine clot model.

Authors:  Christy K Holland; Sampada S Vaidya; Saurabh Datta; Constantin-C Coussios; George J Shaw
Journal:  Thromb Res       Date:  2007-09-14       Impact factor: 3.944

8.  A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.

Authors:  M S Runge; T Quertermous; P J Zavodny; T W Love; C Bode; M Freitag; S Y Shaw; P L Huang; C C Chou; D Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 9.  Left atrial thrombus in a 10-month-old boy--successful thrombolysis with recombinant tissue-type plasminogen activator after open-heart surgery: review of the literature.

Authors:  H G Kehl; D Kececioglu; H Vielhaber; S Kotthoff; M Weyand; G Jorch; J Vogt; U Nowak-Göttl
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

10.  Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.

Authors:  J I Weitz; B Leslie; J Hirsh; P Klement
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.